The European Medicines Agency (EMA) has published an implementation guide for national competent authorities (NCAs) on the European Shortages Monitoring Platform (ESMP), a centralised IT system designed to enhance the monitoring and reporting of medicine shortages across the EU. The guide, released on 28 April 2026, outlines technical and operational requirements for NCAs to connect to the platform, including data submission protocols, system architecture, and security measures. It aims to streamline communication between NCAs, the EMA, and marketing authorisation holders, thereby improving crisis preparedness and response.
The ESMP is a key component of the EU's broader regulatory framework for medicine supply security, as outlined in Regulation (EU) 2022/123 on the reinforced role of the EMA in crisis preparedness and management for medicinal products. The implementation guide provides standardised data formats, mandates real-time reporting of shortages, and recommends integration with existing national systems. This document is a technical guideline, not a binding regulation, but it sets the expected standards for NCAs to ensure interoperability and effective data sharing.
Policy orientations and trade-offs
The guide prioritises standardisation and real-time data exchange, which enhances transparency and early warning capabilities but may impose administrative and technical burdens on NCAs and pharmaceutical companies. The requirement for real-time reporting could improve crisis response but may also increase compliance costs for smaller NCAs with limited IT infrastructure. The trade-off lies between achieving a harmonised EU-wide monitoring system and respecting national autonomy in managing health data.
Impact on stakeholders
- National competent authorities: Will need to adapt their IT systems to meet the ESMP's technical specifications, potentially requiring investment in new software and training. The guide offers flexibility by allowing integration with existing systems, but the standardisation push may still require significant adjustments. - Pharmaceutical companies: Marketing authorisation holders will benefit from streamlined reporting processes and reduced duplication of notifications across member states. However, they may face initial costs to align their data formats with the ESMP's requirements. - Healthcare providers: Improved shortage monitoring could lead to more timely information on medicine availability, aiding in patient care planning. The impact is indirect but positive, as better data can reduce supply disruptions. - Patients: Ultimately, the platform aims to reduce the frequency and duration of medicine shortages, improving access to essential treatments. The effect is long-term and depends on successful implementation by NCAs.
Expected institutional follow-up
The EMA will likely monitor the adoption of the guide by NCAs and may issue updates based on feedback. The European Commission could use the ESMP data to inform policy decisions on medicine supply security. No immediate legislative action is expected, as the guide supports existing regulations.
← Atlas › News › Health & Lifestyle